WASHINGTON, and MENLO PARK, Calif., Oct. 25 /PRNewswire/ -- Evalve, Inc., a privately held medical device company, today announced that investigators presented core laboratory data at the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting in Washington, D.C. showing Evalve's MitraClip can significantly reduce mitral regurgitation (MR) and that the device is durable for up to three years.
